In vitro-in vivo activity relationship of substituted benzimidazole cell division inhibitors with activity against Mycobacterium tuberculosis

Tuberculosis

Volumn 94, Issue 3, 2014, Pages 271-276

  Knudson, Susan E ^a   Kumar, Kunal ^b   Awasthi, Divya ^b   Ojima, Iwao ^b   Slayden, Richard A ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Benzimidazole; FtsZ inhibitor; In vitro activity; In vivo efficacy; Murine model tuberculosis; Mycobacterium tuberculosis

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; RIFAMPICIN; SB P 1G 10; SB P 3G 2; SB P 8B 2; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; BENZIMIDAZOLE; DRUG COMBINATION; OXYGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS; ANIMAL; CELL DIVISION; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; PATHOLOGY; PROCEDURES;

ANIMALS; ANTITUBERCULAR AGENTS; BENZIMIDAZOLES; CELL DIVISION; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OXYGEN; RIFAMPIN; TUBERCULOSIS;

EID: 84900826763     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2014.03.007     Document Type: Article

References (21)

1. Anon Tuberculosis fact sheet 2010 World Health Organization
2. M.C. Raviglione, and I.M. Smith XDR tuberculosis - implications for global public health N Engl J Med 356 2007 656 659 10.1056/NEJMp068273
3. G.B. Migliori, G. De Iaco, G. Besozzi, R. Centis, and D.M. Cirillo First tuberculosis cases in Italy resistant to all tested drugs Euro Surveill 12 2007 E070517 070511
4. R.A. Slayden, D.L. Knudson, and J.T. Belisle Identification of cell cycle regulators in Mycobacterium tuberculosis by inhibition of septum formation and global transcriptional analysis Microbiology 152 2006 1789 1797 10.1099/mic.0.28762-0
5. R.A. Slayden, and J.T. Belisle Morphological features and signature gene response elicited by inactivation of FtsI in Mycobacterium tuberculosis J Antimicrob Chemother 63 2009 451 457 10.1093/jac/dkn507
6. K. Kumar, D. Awasthi, W.T. Berger, P.J. Tonge, R.A. Slayden, and I. Ojima Discovery of anti-TB agents that target the cell-division protein FtsZ Future Med Chem 2 2010 1305 1323 10.4155/fmc.10.220
7. Q. Huang, P.J. Tonge, R.A. Slayden, T. Kirikae, and I. Ojima FtsZ: a novel target for tuberculosis drug discovery Curr Top Med Chem 7 2007 527 543
8. Q. Huang, F. Kirikae, T. Kirikae, A. Pepe, A. Amin, L. Respicio, R.A. Slayden, P.J. Tonge, and I. Ojima Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as novel antituberculosis agents J Med Chem 49 2006 463 466 10.1021/jm050920y
9. K. Kumar, D. Awasthi, S.Y. Lee, I. Zanardi, B. Ruzsicska, S. Knudson, P.J. Tonge, R.A. Slayden, and I. Ojima Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents J Med Chem 54 2011 374 381 10.1021/jm1012006
10. M. Mueller, A. de la Pena, and H. Derendorf Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC Antimicrob Agents Chemother 48 2004 369 377 10.1128/aac.48.2.369-377.2004
11. H. Eagle, and A.D. Musselman The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms J Exp Med 88 1948 99 131
12. C. Miller, L.E. Thomsen, C. Gaggero, R. Mosseri, H. Ingmer, and S.N. Cohen SOS response induction by beta-lactams and bacterial defense against antibiotic lethality Science 305 2004 1629 1631
13. N.Q. Balaban, J. Merrin, R. Chait, L. Kowalik, and S. Leibler Bacterial persistence as a phenotypic switch Science 305 2004 1622 1625 10.1126/science.1099390
14. J.C. Camus, M.J. Pryor, C. Medigue, and S.T. Cole Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv Microbiology 148 2002 2967 2973
15. T. Miyoshi-Akiyama, K. Matsumura, H. Iwai, K. Funatogawa, and T. Kirikae Complete annotated genome sequence of Mycobacterium tuberculosis Erdman J Bacteriol 194 2012 2770 10.1128/JB.00353-12
16. A.J. Lenaerts, V. Gruppo, J.V. Brooks, and I.M. Orme Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice Antimicrob Agents Chemother 47 2003 783 785
17. B.P. Kelly, S.K. Furney, M.T. Jessen, and I.M. Orme Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis Antimicrob Agents Chemother 40 1996 2809 2812
18. R.A. Slayden, R.E. Lee, and C.E. Barry III Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis Mol Microbiol 38 2000 514 525
19. L. Collins, and S.G. Franzblau Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium Antimicrob Agents Chemother 41 1997 1004 1009
20. A.J. Lenaerts, V. Gruppo, K.S. Marietta, C.M. Johnson, D.K. Driscoll, N.M. Tompkins, J.D. Rose, R.C. Reynolds, and I.M. Orme Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models Antimicrob Agents Chemother 49 2005 2294 2301 10.1128/AAC.49.6.2294-2301.2005
21. V.M. Reddy, L. Einck, K. Andries, and C.A. Nacy In vitro interactions between new antitubercular drug candidates SQ109 and TMC207 Antimicrob Agents Chemother 54 2010 2840 2846 10.1128/AAC.01601-09